217 related articles for article (PubMed ID: 9382809)
1. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo.
Böttger A; Böttger V; Sparks A; Liu WL; Howard SF; Lane DP
Curr Biol; 1997 Nov; 7(11):860-9. PubMed ID: 9382809
[TBL] [Abstract][Full Text] [Related]
2. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
4. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
[TBL] [Abstract][Full Text] [Related]
5. Mdm2 promotes the rapid degradation of p53.
Haupt Y; Maya R; Kazaz A; Oren M
Nature; 1997 May; 387(6630):296-9. PubMed ID: 9153395
[TBL] [Abstract][Full Text] [Related]
6. MDMX: a novel p53-binding protein with some functional properties of MDM2.
Shvarts A; Steegenga WT; Riteco N; van Laar T; Dekker P; Bazuine M; van Ham RC; van der Houven van Oordt W; Hateboer G; van der Eb AJ; Jochemsen AG
EMBO J; 1996 Oct; 15(19):5349-57. PubMed ID: 8895579
[TBL] [Abstract][Full Text] [Related]
7. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
Swaroop M; Sun Y
Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
[TBL] [Abstract][Full Text] [Related]
8. Regulation of p53 stability by Mdm2.
Kubbutat MH; Jones SN; Vousden KH
Nature; 1997 May; 387(6630):299-303. PubMed ID: 9153396
[TBL] [Abstract][Full Text] [Related]
9. Defective p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with mdm2 gene amplification.
Knights CD; Liu Y; Appella E; Kulesz-Martin M
J Biol Chem; 2003 Dec; 278(52):52890-900. PubMed ID: 14555661
[TBL] [Abstract][Full Text] [Related]
10. MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts.
Gentiletti F; Mancini F; D'Angelo M; Sacchi A; Pontecorvi A; Jochemsen AG; Moretti F
Oncogene; 2002 Jan; 21(6):867-77. PubMed ID: 11840332
[TBL] [Abstract][Full Text] [Related]
11. Functions of the MDM2 oncoprotein.
Freedman DA; Wu L; Levine AJ
Cell Mol Life Sci; 1999 Jan; 55(1):96-107. PubMed ID: 10065155
[TBL] [Abstract][Full Text] [Related]
12. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.
Shimizu H; Burch LR; Smith AJ; Dornan D; Wallace M; Ball KL; Hupp TR
J Biol Chem; 2002 Aug; 277(32):28446-58. PubMed ID: 11925449
[TBL] [Abstract][Full Text] [Related]
13. Binding to the naturally occurring double p53 binding site of the Mdm2 promoter alleviates the requirement for p53 C-terminal activation.
Kaku S; Iwahashi Y; Kuraishi A; Albor A; Yamagishi T; Nakaike S; Kulesz-Martin M
Nucleic Acids Res; 2001 May; 29(9):1989-93. PubMed ID: 11328884
[TBL] [Abstract][Full Text] [Related]
14. Ets1 is required for p53 transcriptional activity in UV-induced apoptosis in embryonic stem cells.
Xu D; Wilson TJ; Chan D; De Luca E; Zhou J; Hertzog PJ; Kola I
EMBO J; 2002 Aug; 21(15):4081-93. PubMed ID: 12145208
[TBL] [Abstract][Full Text] [Related]
15. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53.
Wasylyk C; Salvi R; Argentini M; Dureuil C; Delumeau I; Abecassis J; Debussche L; Wasylyk B
Oncogene; 1999 Mar; 18(11):1921-34. PubMed ID: 10208414
[TBL] [Abstract][Full Text] [Related]
16. Role of the ATPase domain of the Cockayne syndrome group B protein in UV induced apoptosis.
Balajee AS; Proietti De Santis L; Brosh RM; Selzer R; Bohr VA
Oncogene; 2000 Jan; 19(4):477-89. PubMed ID: 10698517
[TBL] [Abstract][Full Text] [Related]
17. p53 activation in chronic radiation-treated breast cancer cells: regulation of MDM2/p14ARF.
Xia L; Paik A; Li JJ
Cancer Res; 2004 Jan; 64(1):221-8. PubMed ID: 14729628
[TBL] [Abstract][Full Text] [Related]
18. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
[TBL] [Abstract][Full Text] [Related]
19. Merlin neutralizes the inhibitory effect of Mdm2 on p53.
Kim H; Kwak NJ; Lee JY; Choi BH; Lim Y; Ko YJ; Kim YH; Huh PW; Lee KH; Rha HK; Wang YP
J Biol Chem; 2004 Feb; 279(9):7812-8. PubMed ID: 14679203
[TBL] [Abstract][Full Text] [Related]
20. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
Liu WL; Midgley C; Stephen C; Saville M; Lane DP
J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]